

06 July 2021

INFORMATION RELEASE

Re: Pregnyl Discontinuation

On 25 February 2021, Merck, Sharp and Dome, manufacturers of Pregnyl 1500IU and 5,000IU, released a statement informing the health sector that they were discontinuing supply. It was anticipated that Australian supply would run out in August.

In late March, Professor Rob McLachlan, Medical Director of Healthy Male, and Professor David Handelsman, Emeritus Director, ANZAC Research Institute, wrote to the PBAC requesting them to make recombinant hCG (Ovidrel[®], MSD), the alternative hCG formulation in Australia but is currently only approved for women under the PBS, available to men and children. This could utilise the same indications and conditions including reimbursement as currently applicable to Pregnyl.

The letter was supported and co-signed by:

- Professor Bu Yeap, President, Endocrine Society of Australia
- Dr Helen Woodhead, President, Australian Paediatric Endocrine Group
- Assoc Professor Prem Rashid, President Elect, Urological Society of Australia and New Zealand
- Prof Luk Rombauts, President, Fertility Society of Australia and New Zealand

Healthy Male has also alerted the office of the Minister for Health with regard to the issue.

Professor McLachlan has been in correspondence with the PBAC and has been informed that the matter will be considered at their July meeting.

Once an official response has been received from the PBAC, we will communicate it through our channels and pass the information onto the ESA, APEG, USANZ and FSA to ensure that all clinicians are informed

Kind regards



Simon von Saldern
CEO